Format

Send to

Choose Destination
Diagn Microbiol Infect Dis. 2019 Feb;93(2):154-158. doi: 10.1016/j.diagmicrobio.2018.09.002. Epub 2018 Sep 10.

Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe.

Author information

1
Motif BioSciences, New York, NY. Electronic address: david.huang@motifbio.com.
2
IHMA, Monthey, Switzerland.
3
Duke University Medical Center, Durham, NC.
4
Summa Health, Akron, OH.
5
Department of Microbiology and Infection, Hampshire Hospitals NHS Foundation Trust, UK.
6
Department of Pulmonology, Hospital Clinic of Barcelona, University of Barcelona, Institut D'investigacions August Pi I Sunyer, and Centro de Investigación Biomedica En Red-Enfermedades Respiratorias, Barcelona, Spain.
7
Leeds Teaching Hospitals & University of Leeds, Leeds, UK.

Abstract

Iclaprim is a diaminopyrimidine, which inhibits bacterial dihydrofolate reductase, and surveillance data prior to 2006 suggested that iclaprim was active against Gram-positive pathogens including emerging drug-resistant pathogens. In an era of increasing antimicrobial resistance, we undertook testing iclaprim and comparators against 931 Gram-positive clinical isolates from the United States and Europe collected between 2015 and 2016. Susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum inhibitory concentration (MIC) interpretations were based on CLSI and European Committee on Antimicrobial Susceptibility Testing criteria. MIC50/MIC90 was 0.03/0.12 for all Staphylococcus aureus, 0.06/0.06 for methicillin-susceptible S. aureus, 0.03/0.12 for methicillin-resistant S. aureus, 0.12/0.5 for Streptococcus agalactiae, ≤0.015/≤0.015 for Streptococcus anginosus, 0.03/0.06 for Streptococcus dysgalactiae, and ≤0.015 /0.03 μg/mL for Streptococcus pyogenes. Iclaprim was active against a contemporary collection (2015-2016) of Gram-positive bacteria isolated from the skin or soft tissue from patients with SSSI from the United States and Europe.

KEYWORDS:

Iclaprim; In vitro; Skin; Soft tissue; Surveillance

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for White Rose Research Online
Loading ...
Support Center